KRAS G12C inhibitors and methods of using the same

US12440491B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-12440491-B2
Application numberUS-202318213464-A
CountryUS
Kind codeB2
Filing dateJun 23, 2023
Priority dateMay 4, 2018
Publication dateOct 14, 2025
Grant dateOct 14, 2025

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

First claim

Opening claim text (preview).

What is claimed: 1. A method of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound, wherein the compound is

Assignees

Inventors

Classifications

  • C07D471/04Primary

    Ortho-condensed systems · CPC title

  • directly linked by a ring-member-to-ring-member bond · CPC title

  • against tumor tissues, cells, antigens · CPC title

  • Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems · CPC title

  • Antineoplastic agents · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US12440491B2 cover?
Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
Who is the assignee on this patent?
Amgen Inc
What technology area does this patent fall under?
Primary CPC classification C07D471/04. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Oct 14 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).